The ATP binding cassette transporters A1 and G1 (ABCA1/G1) and scavenger receptor class B type (SR-B ) are key molecules in cholesterol efflux and atherogenesis. These genes are regulated by peroxisome proliferator-activated receptor (PPAR ) and liver X receptor (LXR). Telmisartan is an angiotensin type 1 receptor blocker which has been reported to act as a ligand for PPAR . We investigated whether PPAR -activating ARBs affect the expression of these genes and cholesterol efflux from macrophages. Methods and Results: Telmisartan increased ABCA1, ABCG1 and SR-B mRNA levels in THP-1 macrophages in a dose-and time-dependent fashion. It also increased their protein levels and enhanced apoA--and HDL-mediated cholesterol efflux from macrophages. The knockdown of PPAR by siRNA abolished the telmisartan-induced expression of these genes. The knockdown of LXR resulted in the complete and partial abolishment of telmisartan-induced ABCA1 and ABCG1 expression, respectively. We also demonstrated that telmisartan-induced SR-B expression was dependent on the PPAR pathway but not on the LXR pathway. A luciferase assay using an ABCA1 promoter construct showed that telmisartan activated ABCA1 transcription, which was abolished if the LXR binding element was mutated, indicating that increased ABCA1 transcription by telmisartan is LXRdependent. Conclusion: Our results showed that telmisartan enhanced both apoA--and HDL-mediated cholesterol efflux from macrophages by increasing ABCA1, ABCG1 and SR-B expression via PPAR -dependent and LXR-dependent/independent pathways.
Introduction
The renin-angiotensin system plays an important role not only in the regulation of blood pressure but also in the development of atherosclerosis. After binding to their respective receptors, angiotensin and insulin reportedly share a signal transduction pathway 1) . On the other hand, angiotensin inhibits the meta-bolic actions of insulin via the phosphatidylinositol 3-kinase pathway 2) , resulting in insulin resistance. Angiotensin type 1 receptor (AT1R) blockers (ARBs) and angiotensin-converting enzyme inhibitors, which function as antihypertensive agents, have been reported to prevent atherosclerosis in a study using monkeys 3) , improve insulin resistance 4) , and induce a favorable lipid profile 5, 6) . Besides their metabolic effect on insulin signaling, telmisartan 7, 8) and irbesartan 7) , two ARBs, have been found to activate peroxisome proliferator-activated receptor (PPAR ) in cells derived from rodents and this is independent of their AT1R blocking actions.
Recent evidence shows that a transcriptional cas-cade in the PPAR and liver X receptor (LXR) pathways is important for maintaining cellular cholesterol homeostasis in macrophages 9, 10) and activating PPAR results in increased LXR expression, which in turn transactivates the target genes 9) . LXR and/or PPAR reportedly up-regulated the ATP binding cassette transporters (ABC) A1 9, 11) , and ABCG1 12, 13) and scavenger receptor class B type (SR-B ) 14) , all of which facilitate cellular cholesterol efflux 12, [15] [16] [17] [18] . The deletion of PPAR 9, 19) , LXR 20) , ABCA1 21) , ABCG1 22) , and SR-B 23) in macrophages reportedly accelerates the development of atherosclerosis and treatment with LXR 24) and PPAR 25) ligands inhibits its development; however, it is still not clear whether PPAR -activating ARBs affect the expression of these genes and cholesterol efflux from macrophages, and regulate PPARinducible genes in human cells 26) .
In this study, we demonstrated that telmisartan increased ABCA1, ABCG1 and SR-B expression and enhanced apolipoprotein (apo) A--and high density lipoprotein (HDL)-mediated cholesterol efflux from THP-1 macrophages. The telmisartan-induced expression of these genes was regulated by PPAR activation in both an LXR -dependent and independent manner.
Methods

Materials
Telmisartan (Boehringer Ingelheim, Ingelheim, Germany), pioglitazone (Takeda Chemical Industries, Osaka, Japan), losartan (Cayman Chemical, Ann Arbor, MI, USA) and 22(R)-hydroxy cholesterol (22HC; Sigma, St. Louis, MO, USA) were dissolved in dimethylsulfoxide (Sigma). Human apo A-was purchased from Sigma, and human HDL2 and HDL3 subfractions from Acris Antibodies GmbH (Hiddenhausen, Germany).
Cell Culture
THP-1 cells (Riken Cell Bank, Tokyo, Japan) were maintained in RPMI 1640 (Sigma) containing 10% fetal bovine serum (FBS). The differentiation of THP-1 monocytes into macrophages was induced in the presence of 200 nM of phorbol 12-myristate 13-acetate (PMA; Wako, Tokyo, Japan) for 72 hr. Human peripheral blood monocytes were isolated using the method of Fogelman et al. 27) with Ficoll/Hypaque gradient centrifugation. The mononuclear cells thus obtained were re-suspended in RPMI 1640 (Sigma) supplemented with 20% autologous serum, plated onto serumtreated 10-cm dishes and incubated for 2 hr. Non-adherent cells were removed by washing three times with phosphate-buffered saline (PBS), and adherent cells were then detached by incubation in PBS containing 5% autologous serum and 0.02% EDTA at 4 for 30 min. The adherent cells were then washed extensively and re-suspended in RPMI 1640 supplemented with 5% autologous serum. They were then plated on 10-cm dishes and incubated for 10 days so that they would differentiate into macrophages.
Real-time Quantitative RT-PCR
At the indicated hours after treatment with telmisartan and the other compounds, total RNA was extracted from the cells, and first-strand cDNA was synthesized from total RNA (250 ng) by placing in a Reverse Transcription Reagent (Applied Biosystems, Foster City, CA, USA) 28) . Quantitative PCR was performed using a Perkin-Elmer 7900 PCR machine, TaqMan PCR master mix and FAM-labeled TaqMan probes (Assays-on-Demand, Applied Biosystems) for human ABCA1, ABCG1, SR-B , PPAR , LXR , LXR , apoE, CD11b and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Expression data were normalized for GAPDH levels.
Western Blot Analyses
Cells were harvested and protein extracts prepared as previously described 28) . They were then subjected to Western blot analyses (10% SDS-PAGE; 30 g protein per lane) using rabbit anti-ABCA1-(Novus Biologicals, Littleton, CO, USA), ABCG1-(Novus Biologicals), SR-B -(Novus Biologicals), mouse anti-LXR -(PPMX, Tokyo, Japan) and -actin (Santa Cruz, Santa Cruz, CA, USA)-specific antibodies. The proteins were visualized using a chemiluminescence method (ECL Plus Western Blotting Detection System; Amersham Biosciences, Foster City, CA, USA).
Determination of Cholesterol Efflux
Cholesterol efflux experiments were performed as previously described 28) . After 72 hr of THP-1 monocyte differentiation into macrophages, the macrophages so produced were labeled with [ 3 H]cholesterol (1.0 Ci/mL) in RPMI 1640 containing 0.2% bovine serum albumin (BSA) for 20 hr. The cells were washed twice with PBS and incubated for 24 hr in RPMI 1640 containing 0.2% BSA plus telmisartan (20 M), pioglitazone (10 M) or the vehicle. The macrophages were again washed with PBS and incubated in RPMI 1640 containing 0.2% BSA in the presence and absence of apoA-(10 g/mL), HDL2 (50 g/mL) or HDL3 (50 g/mL), for 24 hr. The percentage cholesterol efflux was calculated by dividing media-derived radioactivity by the sum of the radioactivity in the media and cells.
PPAR Activity Assay
PPAR transcription factor activity was assayed using an enzyme-linked immunosorbent assay-based PPAR transcription factor activity assay kit to detect and confirm transcription PPAR factor activation (Active Motif, Carlsbad, CA, USA). THP-1 macrophages were treated with telmisartan, pioglitazone or vehicle for 2 hr. The cells were then rinsed, and nuclear protein was extracted according to the manufacturer's instructions. Nuclear extracts were added to a 96-well plate that had been immobilized by an oligonucleotide containing peroxisome proliferator-response elements (5'-AACTAGGTCAAAGGTCA-3'). After 1 hr, the wells were incubated with diluted primary PPAR antibody to recognize the accessible epitope on PPAR protein upon DNA binding. The horseradish peroxidase-conjugated secondary antibody was added and incubation conducted for 1 hr. At the end, the reaction was stopped, and absorbance was read at 450 nm on a spectrophotometer. This assay is specific for PPAR activation, and there is no cross-reaction with PPAR or PPAR .
siRNA-mediated Macrophage RNA Interference
Human PPAR -and LXR -specific small interfering RNA (siRNA) and scrambled control RNA oligonucleotides were purchased from Ambion Inc. (Austin, TX, USA). The transfection of siRNA was performed using TransIT-TKO Transfection Reagent according to the manufacturer's instructions (Mirus Bio Corporation, Madison, WI, USA). Briefly, 40 nM of scrambled control RNA oligonucleotide or either PPAR -siRNA or LXR -siRNA were added to THP-1 cells 48 hr after treatment with PMA for differentiation. The cells were incubated for a further 24 hr, washed and then the indicated doses of telmisartan and pioglitazone were added. The cells were harvested 24 hr later and mRNA levels determined using RT-PCR. The oligonucleotide sequences used to construct siRNA used in this study were: 5'-GGAUGCAAGGGUUUCUUCCtt-3' and 5'-GGAAGAAACCCUUGCAUCCtt-3' for PPAR (PPAR -siRNA); and 5'-GGAGUGUGUCCUGUCAGAAtt-3' and 5'-UUCUGACAGGACACACUCCtc-3' for LXR (LXRsiRNA).
Construction of Luciferase Reporter Plasmids, DNA Transfection and Luciferase Assays
Luciferase reporter plasmids, ABCA1-Luc and ABCA1-Luc DR4mut, which respectively contain the human ABCA1 promoter region spanning 940 to 110 bp with or without mutations in direct repeat 4 (DR4), were constructed as previously described 28) . Forty-eight hr after treatment with PMA, THP-1 cells were transfected with 1.8 g of ABCA1-Luc or ABCA1-Luc DR4mut and 0.1 g of phRL-TK (Promega) per well using the TransIT-TKO Transfection Reagent. Twenty-four hr after transfection, the media were replaced with RPMI 1640 containing 5% FBS, with or without the indicated doses of telmisartan, pioglitazone or 22HC, and incubated for an additional 24 hr. Luciferase assays were performed as previously described 28) .
Statistical Analysis
ANOVA and the Mann-Whitney U test were performed for statistical analysis as appropriate. Statistical significance was designated at p 0.05. Values are expressed as the mean SEM.
Results
Telmisartan Induces ABCA1, ABCG1, SR-B and LXR Gene Expression
Twenty-four hr after treatment with telmisartan, ABCA1, ABCG1, SR-B and LXR mRNA levels in THP-1 macrophages had increased in a dose-dependent manner (1-20 M, Cmax: 1.8 1.1 M) after administration of telmisartan 80 mg to healthy subjects 29) , and similar changes were noted in response to treatment with the PPAR ligand, pioglitazone (Fig. 1A) . The other ARB, losartan, had no significant effect on expression of these genes, suggesting that telmisartan increased their expression independently of its AT1R blocking action (Fig. 1A). Fig. 1B shows that telmisartan produced a marked increase in SR-B and LXR mRNA levels up to 8 hr after treatment, but the real increases in ABCA1 and ABCG1 mRNA levels came after 8 hr and continued after 16 hr. In contrast, there was a decrease in PPAR mRNA levels up to 16 hr which continued to be low thereafter.
We also observed that 10 M of telmisartan significantly increased ABCA1, ABCG1, SR-B and LXR mRNA levels in human monocyte-derived macrophages (Fig. 2) , and that telmisartan and pioglitazone increased PPAR transcription factor activity, using an enzyme-linked immunosorbent assay-based PPAR transcription factor activity assay kit (Fig. 3) . There was no change in LXR mRNA levels after treatment with telmisartan or the other compounds (data not shown).
Telmisartan Increases ABCA1, ABCG1 and SR-B Protein Levels and Cholesterol Efflux from THP-1 Macrophages
Having established that telmisartan increased ABCA1, ABCG1, SR-B and LXR mRNA levels, we HMDM were treated with 20 M of telmisartan, 10 M of pioglitazone or vehicle for 24 hr. Total RNA was extracted and real-time quantitative RT-PCR was performed as described in Materials and Methods to determine ABCA1 mRNA expression levels. The relative ABCA1 mRNA abundance was calculated by dividing the values for the expression levels of ABCA1 by those for GAPDH. The results for 3 samples are presented as the mean SE. p 0.05 versus control. P values were calculated using Mann-Whitney's U test. examined its effect on the protein levels of these molecules and cholesterol efflux from THP-1 macrophages in comparison with pioglitazone. Both telmisartan and pioglitazone increased ABCA1, ABCG1, SR-B and LXR protein levels and this was consistent with the increases in mRNA levels observed (Fig. 4A) . Mirroring the increases in the protein levels of ABCA1, ABCG1 and SR-B they brought about, telmisartan and pioglitazone significantly increased the cholesterol efflux mediated by both apoA-and HDL (Fig. 4B) .
P PA R -a n d L X R -s i R N A At t e n u a t e t h e Stimulatory Effect of Telmisartan on ABCA1, ABCG1 and SR-B mRNA Levels
We used the siRNA approach to determine whether the telmisartan-induced expression of ABCA1, ABCG1 and SR-B is dependent on PPAR and/or LXR . PPAR -and LXR -siRNA suppressed PPAR and LXR mRNA levels by up to 75% and up to 91%, respectively ( Fig. 5A and 5C ). In these experiments, transient transfection of THP-1 macrophages with PPAR -siRNA substantially abolished telmisartan-mediated induction of ABCA1, ABCG1, SR-B and LXR expression (Fig. 5B) . Nonsilencing, scrambled siRNA had no effect. LXR -siRNA also abolished the increase in ABCA1 mRNA levels brought about by telmisartan (Fig. 5D) ; however, it only reduced telmisartan-induced ABCG1 expression by up to 20% and had no effect on the increase in SR-B mRNA levels induced by telmisartan (Fig. 5D) . These findings suggest that telmisartan-induced ABCA1 and ABCG1 expression is mediated by PPAR , and that the effect of telmisartan on ABCA1 and ABCG1 is completely and partially dependent on LXR , respectively. Furthermore, it seems that the increase in SR-B expression due to telmisartan is dependent on PPAR , but not LXR .
Increase in ABCA1 Gene Expression Induced by Telmisartan is Associated with LXR-Dependent Transcriptional Activation
To investigate the effect of telmisartan on ABCA1 promoter activity, ABCA1-Luc was transfected into THP-1 macrophages and a luciferase assay was performed ( Fig. 6 ) in experiments in which telmisartan, pioglitazone and an LXR ligand, 22HC, were added. Telmisartan increased ABCA1 promoter activity in pace with the increase in mRNA levels it brought about (Fig. 6B) . Pioglitazone and 22HC also enhanced transcription of the ABCA1 reporter gene.
It has been reported that LXRs form heterodimers with retinoid X receptor (RXR) and bind to conserved consensus cis-element, DR4, in the ABCA1 promoter region, resulting in the activation of transcrip- . When the DR4 mutant-containing reporter vector (ABCA1-Luc DR4mut, Fig. 6A ) was used, telmisartan had no effect on ABCA1 promoter activity, and neither did pioglitazone or 22HC (Fig. 6B) , indicating that telmisartan-activated ABCA1 transcription is dependent on LXR.
Discussion
Our observations suggest that the effect of telmisartan on the expression of ABCA1, ABCG1, SR-B and LXR is mediated by PPAR activation, and not by AT1R blockade. Schupp et al. 30) observed that typical PPAR ligands and the individual PPAR -activating ARBs, telmisartan and irbesartan, brought about distinct conformational changes in PPAR , which were associated with selective cofactor recruitment and a distinctive gene expression profile, in murine adipocytes. They also demonstrated that pioglitazone and telmisartan differentially regulate ABCA1 (do not change and decrease, respectively) and ABCG1 (decrease and do not change, respectively) expressions in 3T3-L1 adipocytes using DNA microarrays. The discrepancy between their observations and our findings could be due to species-and/or cell-specific regulation of these genes including distinct cofactors involved in the transcriptional machinery. The present study demonstrated telmisartan's PPAR -activating effects in human cells for the first time 26) , and that telmisartan stimulates the PPAR -LXR pathway, resulting in ABCA1/G1 activation, effects which have not been observed in murine adipocytes 30) . The experiments using siRNAs with the objective of suppressing PPAR or LXR expression indicated that the increases in ABCA1 mRNA levels due to telmisartan and pioglitazone were almost completely mediated via the PPAR -LXR pathway. Also, in the assays to measure promoter activity, we found that the increase in ABCA1 transcriptional activity due to telmisartan and pioglitazone was not observed when DR4 was mutated. Furthermore, a recent study 13) noted that a PPAR agonist had a stimulatory effect on ABCA1 expression in wild-type macrophages but not on LXR / LXR double knockout macrophages. These findings indicate that activated PPAR increases ABCA1 mRNA levels at the transcriptional level in an LXR-dependent manner.
After treatment with LXR -siRNA, we noted that telmisartan-induced ABCA1 expression was substantially blocked whereas ABCG1 expression was only partially blocked. In contrast, ABCG1 expression was completely suppressed by PPAR -siRNA. In this regard, Li et al. 13) reported no difference in the stimulatory effect of PPAR agonists on ABCG1 expression between wild-type and LXR /LXR double knockout macrophages, suggesting that the activation of PPARinduced ABCG1 expression is independent of LXR. On the other hand, Laffitte et al. 31) reported that LXR agonist-induced ABCA1 and ABCG1 expressions in macrophages were completely abolished by the deletion of both LXR and LXR . Other studies have shown that the ABCG1 gene is transcriptionally activated by activated LXR through its binding elements 12) . Taken together, the above observations suggest that ABCG1 is regulated via PPAR , both in an LXRdependent and -independent manner, and the LXRindependent effect of PPAR activation on ABCG1 expression could overwhelm the inhibitory effect of LXR knockdown on ABCG1. As it is still not clear whether this LXR-independent effect is mediated by PPAR directly or by other pathways affected by PPAR , we are currently conducting further studies to determine whether ABCG1 is transcriptionally regulated by PPAR .
The present study suggests that both pioglitazoneand telmisartan-mediated induction of SR-B mRNA expression are independent of the LXR pathway. We also found that an LXR agonist brought about no changes in SR-B mRNA levels in macrophages (data not shown). Recently, other researchers have demonstrated that SR-B expression in atherosclerotic lesion macrophages is regulated by PPAR 14) and activated PPAR transcriptionally stimulates hepatic SR-B expression 32) . The SR-B expression in macrophages induced by pioglitazone and telmisartan in our study could be due to a similar mechanism.
The changes in ABCA1, ABCG1, SR-B and LXR levels with time following treatment with telmisartan suggest that SR-B is directly up-regulated by telmisartan-mediated PPAR and, in the case of ABCA1, telmisartan first activates LXR , which then induces ABCA1 transcription, consistent with the results obtained in siRNA experiments. The results of these experiments indicate that the newly produced proteins induced by PPAR and/or activated PPAR could be involved to a major extent in increased ABCG1 expression due to telmisartan, and those induced by LXR might only be partly involved.
Interestingly, telmisartan and pioglitazone downregulated PPAR mRNA levels in THP-1 macrophages in our study. These observations are similar to the findings of Schupp et al. 30) who showed that PPAR mRNA levels were down-regulated after incubation with telmisartan and pioglitazone in murine adipocytes. Since the mechanism for this negative regulation of PPAR expression by its ligands is still unclear, further study is necessary.
Our data show that telmisartan enhanced both apoA--and HDL-mediated cholesterol efflux, and increased ABCA1, ABCG1 and SR-B protein levels, which was consistent with changes in mRNA levels. It has been reported that lipid-poor apoA-contributes to ABCA1-mediated cholesterol efflux from cells, but not HDL 15, 16) . On the other hand, ABCG1 has been reported to promote cholesterol efflux to HDL, but not to apoA- 16, 17) . SR-B is also known to promote HDL-mediated cellular cholesterol efflux 18) . Further, recent research has demonstrated that the deletion of ABCA1 21) , ABCG1 22) , and SR-B 23) in macrophages results in increased atherogenesis. Telmisartan has already been observed to have an anti-atherosclerotic effect in a study using monkeys 3) and all of the above evidence suggests that in this effect, there could be a contribution from its ability to enhance cholesterol efflux from macrophages. Regarding ABCG1, recent studies have reported a decrease in atherosclerosis in mice transplanted with ABCG1-knockout bone marrow 33, 34) ; however, no study has demonstrated the effect of ABCG1 overexpression in macrophages on the development of atherosclerosis. Therefore, further studies are needed to assess whether increased cholesterol efflux from macrophages due to telmisartan-induced ABCG1 expression contributes to the development of atherosclerosis.
There is accumulating evidence showing that PPAR -activating ARBs bring about favorable changes in glucose and lipid metabolism. The combination of this effect and their antihypertensive action could help attenuate the development of atherosclerotic diseases. The present study demonstrates that PPAR activation by telmisartan is part of a novel pathway having possibilities for atherogenesis prevention, in which cholesterol efflux from macrophages is increased, and ABCA1, ABCG1 and SR-B expressions are enhanced. Clinical studies are now needed to investigate whether PPAR -activating ARBs would be superior to non-PPAR -activating ARBs in terms of preventing atherosclerotic diseases.
